Quibim, a company using artificial intelligence to improve cancer diagnostics, is making a major move into the US by hiring a Boston-based chief medical officer
Soon, more patients will benefit from AI technology’s ability to highlight lesions and provide physicians with better data
BOSTON, May 26, 2023 /PRNewswire/ — Earlier cancer detection and more accurate initial diagnosis are two of the key benefits of breakthrough artificial intelligence technology that a European company is now making available to US patients. For Quibim, a leading imaging technology provider in the EU, this journey began with the recent US FDA approval to apply its patented AI-enabled technology to home prostate cancer diagnostics.
With today’s announcement of hiring its first U.S.-based chief medical officer, that journey has now brought the AI-driven company to the hub of medical talent in Boston.
Soon, more patients will benefit from AI technology’s ability to highlight lesions and provide physicians with better data
Tweet this
The widely sought-after oncology expert Dr. Glen J. Weiss, MD, MBA, will serve as Chief Medical Officer for Quibim as the company expands its relationships with hospitals and life science companies across the United States
The move signals a pivotal moment in the proliferation and mainstreaming of AI-based technology into the patient experience in the United States. As an established and major European AI-based imaging provider, Quibim has played a critical role in improving clinical trial design, optimizing drug development and managing large amounts of imaging data, while creating new predictive biomarker panels for imaging that benefit patients, providers and benefit companies like.
Now the company is trying to expand that impact in the US, headed by a chief medical officer with close ties to Massachusetts. While the company will retain its US headquarters in New York, Boston is among the markets where the company expects increased adoption of its AI-driven imaging technology platforms, including “QP-Prostate®”.
According to the American Cancer Society and other Cancer.net sources, prostate cancer is the most common cancer in men, with the exception of skin cancer.
Weiss is a former Harvard Medical School faculty member and was director of Phase I clinical research at Beth Israel Medical Center (BIDMC) and associate member of the BIDMC Cancer Research Institute.
Weiss’ background includes over 100 phase 1-3 oncology studies and extensive experience in biomarker/translational research studies. He has published more than 300 peer-reviewed articles and abstracts in peer-reviewed journals including the New England Journal of Medicine, Journal of Clinical Oncology, Lancet Oncology, Nature Communications, Clinical Cancer Research and Cancer Cell.
“Quibim is revolutionizing medical imaging and driving personalized medicine,” said Angel Alberich-Bayarri, CEO of Quibim. “The expertise and visionary approach of Dr. Weiss will make great contributions to our mission, and we look forward to the exciting opportunities and achievements that lie ahead for our company.”
Quibim’s medical department integrates innovative tools in imaging software and data extraction analysis, as well as in the assessment of therapy efficacy, notably through the possibility of “lesion highlighting” and “volumetric data analysis”.
Quibim strives to be the preferred provider and industry leader for predictive imaging biomarkers, novel diagnostics and IP development for personalized medical imaging solutions. The attitude of Dr. Weiss represents a significant milestone in the growth and development of Quibim in the United States and positions the Company for significant research, exploration, collaboration and business development expansion.
As CMO, Dr. Weiss will lead Quibim’s medical division and provide strategic guidance on personalized medicine, scientific platform development and clinical applications.
“I can envision a future where medical imaging evolves from a diagnostic tool to a dynamic theranostic for clinical drug development,” said Dr. White. “The harmonization of medical solutions, especially in the area of imaging, is crucial to improve the interpretation of real-world evidence and the reporting of clinical trials. Quibim has mastered this.”
About Quibim
Quibim – with offices in New York (USA), Cambridge (UK) and Valencia, Madrid and Barcelona (Spain) – was born out of a desire to transform imaging into a catalyst for precise health. They do this by developing groundbreaking tools that share image data to improve patient outcomes. The brand is connected to the company’s values and is based on a deep understanding of the modern science of imaging data and the search for a way to convert this data into actionable predictions. To achieve this, Quibim is collaborating with world-class biopharmaceutical companies to detect pathologies early and predict outcomes in oncology/immunotherapy, immunology, inflammation and neurology using MRI, CT and PET imaging. This leads to new regulatory approved medical devices being marketed by healthcare providers. The company specializes in the development of AI models created with the help of Real World Evidence (RWE) projects and Biopharma partners to derive new insights from images. Novel quantitative imaging biomarkers are being developed to in-depth analyze disease mechanisms, drive drug development and monitor treatment progress using a whole-body approach.
Media contact:
Hallie Kogelschatz
[email protected]
SOURCE Quibim
